This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The authors did not report whether the sample size was determined in the planning phase of the study. They also did not report any retrospective power calculations. A total of 6,100 patients undergoing non-emergent PCI were enrolled in the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. However, the economic analysis was confined to those patients enrolled at US treatment sites, with 4,651 patients enrolled. Out of these, 2,319 patients were allocated to the bivalirudin group and another 2,332 to the heparin+GP IIb/IIIa group. The mean age in each of the two groups was 63 (+/-11) years. The proportion of males was 72.7% in the bivalirudin group and 72.8% in the heparin+GP IIb/IIIa group.
Study design
The study was a randomised controlled trial (RCT) that was carried out at different treatment sites across the USA. Randomisation was stratified by study site and by the operator's intent to use either abciximab or eptifibatide as the GP IIb/IIIa inhibitor. The groups were followed for 30 days after hospital discharge. The authors reported no loss to followup. The authors reported that the patients were randomised in a double-blind fashion.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. The primary health outcomes used were MI, major bleeding, minor bleeding, death and any repeat revascularisation. MI was defined as either the development of new pathologic Q waves, the elevation of creatine kinase-MB fraction (CKMB) to at least 3 times the upper limit of normal within 48 hours of PCI, or the elevation of CKMB to at least twice the upper limit of normal at any other time during follow-up. Major bleeding was defined as any intracranial or retroperitoneal haemorrhage, clinically overt blood loss resulting in a decrease in haemoglobin greater than 3 g/dL, any decrease in haemoglobin greater than 4 g/dL, or the transfusion of at least 2 U of packed red cells. Minor bleeding was defined as any other clinically overt blood loss that did not meet the criteria for major bleeding. The baseline characteristics of the two treatment groups were wellmatched, except for a modest excess of patients who underwent multi-vessel PCI in the bivalirudin group (17.3% versus 14.6%; p=0.01).
Effectiveness results
During the initial hospitalisation, there was no significant difference in the combined incidence of death or MI between the bivalirudin and heparin+GP IIb/IIIa groups (7.3% versus 6.6%).
Bivalirudin plus provisional GP IIb/IIIa inhibition was associated with a significant and consistent reduction in bleeding complications compared with heparin plus routine GP IIb/IIIa inhibition. Protocol-defined major bleeding was reduced by 38% (2.8% versus 4.5%; p=0.002), minor bleeding was reduced by 46% (15.1% versus 28.1%; p<0.001), and thrombocytopenia (defined as any platelet count less than 100,000/microL) was reduced by 54% (0.7% versus 1.5%; p=0.01).
Between hospital discharge and the 30-day follow up, there were no significant differences in clinical outcomes between the two groups.
Clinical conclusions

Synthesis of costs and benefits
The costs and benefits were not combined. The results of the multiple linear regression showed that repeat revascularisation procedures (in-hospital coronary artery bypass grafting, repeat PCI) were the strongest correlates of inhospital cost. Among procedural complications, major bleeding, thrombocytopenia and large periprocedural MI (CKMB greater than 10 times the upper limit of normal) had the greatest independent impact on cost, whereas small-tomoderate post-procedural MI and minor bleeding had smaller impacts. Several baseline patient characteristics (e.g. need for multi-vessel PCI, acute coronary syndrome presentation, and history of congestive heart failure) were also associated with higher initial hospital costs.
Authors' conclusions
Compared with heparin plus routine glycoprotein (GP) IIb/IIIa inhibition, bivalirudin plus provisional GP IIb/IIIa inhibition resulted in similar acute ischaemic events and cost-savings of $374 to $405 per patient, depending on the analytic perspective.
CRD COMMENTARY -Selection of comparators
A justification was given for the use of heparin plus routine GP IIb/IIIa inhibition. In the past decade, numerous clinical trials had demonstrated that this intervention led to substantial reductions in periprocedural ischaemic complications in comparison with unfractionated heparin alone. You should decide if this is a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The analysis was based on a double-blind RCT. This was appropriate for the study question as well-conducted RCTs, such as this one, are considered the 'gold' standard when comparing different health interventions. The study sample appears to have been representative of the study population, with more than 4,000 patients being recruited, hence increasing the power of the study. The patient groups were generally shown to be comparable at analysis, with the exception that more patients in the bivalirudin group underwent multi-vessel PCI. The clinical analysis was undertaken on an intention to treat basis, and appropriate statistical techniques were used to test for any statistically significant differences between the two groups.
Validity of estimate of measure of benefit
The authors did not derive a measure of health benefit. The analysis was therefore categorised as a cost-consequences study.
Validity of estimate of costs
Although the authors reported that the costs were estimated from a societal perspective, the indirect costs (e.g. productivity losses due to premature death and morbidity) were not included. The perspective actually adopted was that of the third-party payer. The analysis did not include the costs for outpatient medical services and medications and, therefore, the total cost of each intervention may have been overestimated. The costs and the quantities were reported separately, which will increase the generalisability of the authors' results to other settings. Resource use was derived from the single study, with appropriate statistical techniques being used to test for any significant differences between the two groups. The unit costs were derived from several sources, with the majority of costs being derived from Medicare charges. Although charges were used, the authors adjusted charges to the specific cost-to-charge ratio, so that these costs would more accurately depict the actual cost of providing an intervention. The authors performed a multiple linear regression to identify the predictors of initial hospital costs. Discounting was irrelevant, as all the costs were incurred during a short time, and was not performed. The price year was appropriately reported, which will aid any possible inflation exercises.
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